Form 8-K

8-K — iBio, Inc.

Accession: 0001420720-26-000028

Filed: 2026-09-14

Period: 2026-09-14

CIK: 0001420720

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Regulation FD Disclosure

Item: Other Events

Item: Financial Statements and Exhibits

Documents

8-K — ibio-20260914x8k.htm (Primary)

EX-99.1 (ibio-20260914xex99d1.htm)

GRAPHIC (ibio-20260914xex99d1g001.jpg)

GRAPHIC (ibio-20260914xex99d1g002.jpg)

GRAPHIC (ibio-20260914xex99d1g003.jpg)

GRAPHIC (ibio-20260914xex99d1g004.jpg)

GRAPHIC (ibio-20260914xex99d1g005.jpg)

GRAPHIC (ibio-20260914xex99d1g006.jpg)

GRAPHIC (ibio-20260914xex99d1g007.jpg)

GRAPHIC (ibio-20260914xex99d1g008.jpg)

GRAPHIC (ibio-20260914xex99d1g009.jpg)

GRAPHIC (ibio-20260914xex99d1g010.jpg)

GRAPHIC (ibio-20260914xex99d1g011.jpg)

GRAPHIC (ibio-20260914xex99d1g012.jpg)

GRAPHIC (ibio-20260914xex99d1g013.jpg)

GRAPHIC (ibio-20260914xex99d1g014.jpg)

GRAPHIC (ibio-20260914xex99d1g015.jpg)

GRAPHIC (ibio-20260914xex99d1g016.jpg)

GRAPHIC (ibio-20260914xex99d1g017.jpg)

GRAPHIC (ibio-20260914xex99d1g018.jpg)

GRAPHIC (ibio-20260914xex99d1g019.jpg)

GRAPHIC (ibio-20260914xex99d1g020.jpg)

GRAPHIC (ibio-20260914xex99d1g021.jpg)

GRAPHIC (ibio-20260914xex99d1g022.jpg)

GRAPHIC (ibio-20260914xex99d1g023.jpg)

GRAPHIC (ibio-20260914xex99d1g024.jpg)

GRAPHIC (ibio-20260914xex99d1g025.jpg)

GRAPHIC (ibio-20260914xex99d1g026.jpg)

GRAPHIC (ibio-20260914xex99d1g027.jpg)

GRAPHIC (ibio-20260914xex99d1g028.jpg)

GRAPHIC (ibio-20260914xex99d1g029.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: ibio-20260914x8k.htm · Sequence: 1

iBio, Inc._September 14, 2026

0001420720false00014207202026-09-142026-09-14

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): September 14, 2026

iBio, Inc.

(Exact name of registrant as specified in charter)

Delaware

(State or other jurisdiction of incorporation)

001-35023

26-2797813

(Commission File Number)

(IRS Employer Identification No.)

11750 Sorrento Valley Road, Suite 200

San Diego, California 92121

(Address of principal executive offices and zip code)

(979) 446-0027

(Registrant’s telephone number including area code)

N/A

(Former Name and Former Address)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.001 par value per share

IBIO

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 7.01. Regulation FD Disclosure.

iBio, Inc. (the “Company”) has updated its corporate presentation. A copy of the updated corporate presentation is filed as Exhibit 99.1 to this Current Report on Form 8-K.

The corporate presentation attached as Exhibit 99.1 to this Current Report on Form 8-K includes “safe harbor” language pursuant to the Private Securities Litigation Reform Act of 1995, as amended, indicating that certain statements contained therein are “forward-looking” rather than historical.

The Company undertakes no duty or obligation to update or revise the information contained in this Current Report on Form 8-K, although it may do so from time to time if its management believes it is appropriate. Any such updating may be made through the filing of other reports or documents with the Securities and Exchange Commission, through press releases or through other public disclosures.

Item 8.01. Other Events.

The Company has updated its corporate presentation for use in meetings with investors, analysts and others. A copy of the updated corporate presentation is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.

Description

99.1

Corporation Presentation of iBio, Inc., dated September 2026

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: September 14, 2026

IBIO, INC.

By:

/s/ Marc A. Banjak

Name:

Marc A. Banjak

Title:

Chief Legal Officer

EX-99.1

Filename: ibio-20260914xex99d1.htm · Sequence: 2

Exhibit 99.1

BREAKTHROUGH

ANTIBODIES FOR

OBESITY AND

CARDIOMETABOLIC

DISEASES

CORPORATE PRESENTATION • September 2026

Certain statements in this presentation constitute "forward

-looking statements" within the meaning of the Private Securities Litigation Reform

Act of 1995

, as amended

. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict,"

"forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward

-looking

statements

. These forward

-looking statements are based upon current estimates and includes statements regarding near term catalysts

. While

iBio

, Inc

a Delaware corporation (including its consolidated subsidiaries,

“iBio,” the “Company,” “we,” “us” or “our”) believes these forward

looking statements are reasonable, undue reliance should not be placed on any such forward

-looking statements, which are based on

information available to us on the date of this presentation

. These forward

-looking statements are subject to various risks and uncertainties,

many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those

set forth or implied by any forward

-looking statements

. Important factors that could cause actual results to differ materially from current

expectations include, among others, the Company’s ability to obtain regulatory approvals for commercialization of its product candidates, or to

comply with ongoing regulatory requirements, regulatory limitations relating to its ability to promote or commercialize its product candidates for

specific indications, acceptance of its product candidates in the marketplace and the successful development, marketing or sale of products, its

ability to attain license agreements, the continued maintenance and growth of its patent estate, its ability to establish and maintain

collaborations, its ability to obtain or maintain the capital or grants necessary to fund its research and development activities, competition, its

ability to retain its key employees or maintain its Nasdaq Stock Market listing, and the other factors discussed in the Company’s most recent

Annual Report on Form 10

K and the Company’s subsequent filings with the SEC, including subsequent periodic reports on Forms 10

Q and

. The information in this presentation is provided only as of today, and we undertake no obligation to update any forward

-looking statements

contained in this presentation on account of new information, future events, or otherwise, except as required by law

Disclaimer

. This presentation has been prepared by the Company solely for informational purposes

. Certain of the information included herein

was obtained from various sources, including certain third parties, and has not been independently verified by the Company

. By viewing or

accessing the information contained in this presentation, you hereby acknowledge and agree that no representations, warranties, or

undertakings, express or implied, are made by the Company or any of its directors, shareholders, employees, agents, affiliates, advisors, or

representatives as to, and no reliance should be placed on the truth, accuracy, fairness, completeness, or reasonableness of the information or

opinions presented or contained in, and omission from, this presentation

. Neither the Company nor any of its directors, employees, agents,

affiliates, advisors, or representatives shall be responsible or liable whatsoever (in negligence or otherwise) for any loss, howsoever arising

from any information presented or contained in this presentation or otherwise arising in connection with the presentation, except to the extent

required by applicable law

This presentation includes statistical and other industry and market data that we obtained from industry publications and research, surveys, and

studies conducted by third parties, and our own estimates of potential market opportunities

. All of the market data used in this presentation

involves

a number of assumptions and limitations, and you are cautioned not to give undue weight to such data

. Industry publications and third

party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although

they do not guarantee, and we have not independently verified, the accuracy or completeness of such information

. Our estimates of the

potential market opportunities for our product candidates include several key assumptions based on our industry knowledge, industry

publications, third

-party research, and other surveys, which may be based on

a small sample size and may fail to accurately reflect market

opportunities

. While we believe that our internal assumptions are reasonable, no independent source has verified such assumptions

Forward Looking Statements

KFF Health Tracking Poll May 2024: The Public’s Use and Views of GLP-1 Drugs, KFF, May 10, 2025 3

Revolution Sparked a New Era in

Obesity Treatment

Incretin Class Agonists Have

Revolutionized Obesity Treatment

>10% of American adults have taken

a GLP-11

Interventional weight loss previously

only achievable via surgery

Evolution Will Define Its Future

Attention is Shifting to Therapies

That Build on That Foundation

Durability of weight loss

Lean mass preservation and fat-specific

weight loss

Improved tolerability and convenience

The GLP-1 Revolution Unlocked Possibility:

We Aim to Drive the Future Evolution

1. Beavers et al (2011), Am J Clin Nutr. 94:767-74

2. Johnson et al (2017), J Bone Miner Res. 32(11):2278-2287 4

GLP-1

Treatment

start

GLP-1

Treatment

stop

Obesity + Cardiovascular

Complication Risk

Healthy Weight

“For every 1 kg weight lost…

0.32 kg lean tissue was lost

and for every 1 kg weight

regained…, only 0.08 kg lean

tissue was regained”1

“Compared to (control) group, the

[weight loss/regain] group had a

statistically significant 39%

increased risk of a frailty

fracture”2

“

Portfolio Approach to Obesity: Targeting Multiple Mechanisms

to Deliver Next-Generation Therapies, Beyond Incretins

Designed to improve

quality of weight loss not

met by GLP-1’s

• Prevent muscle loss

• Reduce adverse effects

and discontinuation

• Increase the duration of

weight loss

• Improve dosing frequency

Broad portfolio of highly

validated targets

• Fat-specific weight loss

• Targets calories and

energy with less side

effects

• Preserve and increase

muscle mass

Differentiated high-value

pipeline

• Intended to solve

complex, hard-to-drug

targets

• Optimize both function

and developability

• Rapid development of

unique multi-specifics

Next Generation

Antibodies for Obesity

Targeting Key Gaps in

Current Care

Corporate Highlights

Lead Programs

IBIO-610: Long-acting Activin E

antibody

IBIO-800: Myostatin x Activin A

bispecific antibody

IBIO-600: Long-acting Myostatin

antibody

Pipeline

4 high novelty programs and 1

partnered program

Discovery to development candidate

in as little as 7 months

AI engine delivers precisely

targeted antibodies with promising

developability

Anticipated Near

Term Catalysts

IBIO-800 IND

equivalent filing

expected in 1H 2027

IBIO-610 IND equivalent

filing expected in 2H 2026

IBIO-610 Phase 1

expected to be initiated

in 1H 2027

IBIO-600 Interim Phase 1

data anticipated in 1Q 2027

iBio’s Strategy in Motion: Advancing Next-Gen Treatments Beyond First-Gen

Obesity Drugs

Program is in-licensed from AstralBio, Inc *Spinal Muscular Atrophy 7

CARDIOMETABOLIC STAGE

Discovery Optimization IND Enabling Phase 1

IBIO-800

PH-HFpEF, Obesity

CARDIOMETABOLIC STAGE

Discovery Optimization IND Enabling Phase 1

IBIO-600 Myostatin Antibody

Obesity, SMA*, Sarcopenia,

Other muscle-loss disorders

CARDIOMETABOLIC STAGE

Discovery Optimization IND Enabling Phase 1

Amylin Antibody

Obesity

CARDIOMETABOLIC STAGE

Discovery Optimization IND Enabling Phase 1

Target 4

Obesity

CARDIOMETABOLIC STAGE

Discovery Optimization IND Enabling Phase 1

IBIO-610 Activin E Antibody

Obesity

IND equivalent filing expected in 2H 26

First patient dosed expected in 1H 27

IND equivalent filing

expected in 1H 2027

Interim data

anticipated 1Q 2027

PARTNERED WITH

ANTICIPATED UPCOMING MILESTONES

DC Candidates 2H

2027

IBIO-610

Activin E Antibody

IBIO-610: Long-acting Antibody against Activin E

A Novel Target in Obesity

IBIO-610 is being positioned as a differentiated antibody approach being studied to

improve body composition and extend the commercial reach of incretin-based therapies

1. Akbari, P. et al. Multiancestry exome sequencing reveals INHBE mutations associated with favorable fat distribution and protection from diabetes. Nat Commun 13, 4844 (2022).

2. Deaton, A. M. et al. Rare loss of function variants in the hepatokine gene INHBE protect from abdominal obesity. Nat Commun 13, 4319 (2022).

Type 2 Diabetes (T2D); Loss of Function (LOF)

Novel, Genetically Validated

Target

• Liver-derived hepatokine tied to

adipose metabolism

• LOF genetics linked to

favorable fat distribution and

lower T2D risk1,2

• Differentiated from incretins,

complementary non-appetite

pathway

Activin E / INHBE

Direct, Potent and Durable

Neutralization

• Near-complete suppression of

circulating free Activin E

• Designed for convenience -

long-acting subcutaneous

dosing

• Antibody optimized for high

developability and

manufacturability at large

scales

Quality and Durability Of

Weight Loss

• Potential for greater, more

durable fat loss while

preserving lean mass

• Addresses body composition

through a distinct mechanism

from appetite suppression

• Potential utility across

combination, maintenance,

and stand-alone use

Therapeutic + Commercial Fit Why our Antibody?

IBIO-610 Demonstrates Extended Half-Life and Achieves Near-Complete

Suppression of Activin E in Obese Non-Human Primates

Non-Human Primates (NHP); Age 8-15 years, 18-51% body fat, n=4-6 per group, 10mg/kg IV dose at week 0; terminal half-life determined from linear portion of PK curve, active Activin E levels

measured, and percent suppression calculated at week 8 based on average change from baseline active Activin E levels; dotted line represents assay LLOQ, 80 pg/mL. Data on file

0 20 40 60

100

1000

Obese NHP Pharmacokinetics

Day

IBIO-610 in serum

(ug/mL)

t1/2, NHP = 33.2 days

Obese NHP Activin E Suppression

≥97% Suppression

0 2 4 6 8

500

1000

1500

Week

Activin E (pg/mL)

Vehicle

IBIO-610

Dose

Week 0 Week 8

DEXA

MRI

DEXA

MRI

Week -4

IBIO-610

Obese NHP Pharmacokinetics

IBIO-610 Shows Selective Fat Reduction and Lean Mass Preservation in

Obese Non-Human Primates

Non-Human Primates (NHP); Age 8-15 years, 18-51% body fat, n=4-6 per group, 10mg/kg IV dose at week 0 and week 8; Total fat mass and total lean mass determined via DEXA at baseline and

week 16; visceral fat determined by abdominal MRI at baseline and week 16 Data on file 11

Group 1 Vehicle

Group 2 IBIO-610

% Change from Baseline

Week 16

-6.7%

-5.2% +0.9%

Data IBIO-610

(NHP)

Reduction visceral fat -6.7%

Reduction total fat -5.2%

Increase lean mass +0.9%

Body Composition in NHPs After

Activin E Pathway Inhibition Visceral Fat

Week 16

Total Fat Mass

Week 16

Total Lean Mass

Dose

Week 0 Week 8

DEXA

MRI

DEXA

MRI

Week -4

IBIO-610

Week 16

DEXA

MRI

Dose

IBIO-610 Improves the Quality of GLP-1-Induced Weight Loss in Obese

NHPs

Non-Human Primates (NHP); Age 8-15 years, 18-51% body fat, n=6 per group, IBIO-610 dosed 10mg/kg IV dose at week 0; Semaglutide titrated up to 30 ug/kg and administered BIW,

subcutaneously. Total fat mass and total lean mass determined via DEXA at baseline and week 8; Approximately 1% of body mass change is neither lean nor fat mass. Data on file 12

0 2 4 6 8

-20

-15

-10

-5

Week

Body Weight

% change baseline

Sema

Sema + IBIO-610

Sema Sema +

IBIO-610

500

1000

1500

Mass Loss (g)

Fat

Lean 77%

22%

93%

Sema Sema +

IBIO-610

-10

-5

Lean Mass

% Change from Baseline

Lean tissue was 22% of mass lost with semaglutide alone vs 6% in combination

Sema Sema +

IBIO-610

-40

-20

Fat Mass

% Change from Baseline

Fat Mass

Body Weight

Lean Mass Composition of Weight Loss

Dose

Week 0 Week 8

DEXA DEXA

Week -4

IBIO-610

IBIO-600

Long-Acting Myostatin

Antibody

IBIO-600: Differentiated Long-Acting Anti-Myostatin Program

Improved

Pharmacokinetics

Potential best-in-class PK based on allometric scaling and

dosing regimen suggests 2-4x improved half-life over

competitors

Dual Mechanism Dual myostatin and GDF11 blockade has potential for improved

lean mass preservation and fat mass reduction

Enhanced

Manufacturability

Optimized for high expression and stability to enable

efficient manufacturing process

Coformulation

Optionality

High formulation concentration to reduce subcutaneous

injection volume

Convenience NHP T1/2 of 52.4 days means that administration as infrequent as

twice a year may be feasible

IBIO-600: Selective target inhibition, extended T1/2 and improved body

composition in NHPs

Baseline human

myoblast differentiation1

Myostatin inhibits

myoblast differentiation

IBIO-600 blocks Myostatin

and increases myoblast

differentiation

0.1 1 10 100 1000

IBIO-600 (nM)

Fusion index

Myostatin only

IBIO-600

0.1 1 10 100 1000

IBIO-600 (nM)

Fusion index

GDF11 only

IBIO-600

Myostatin GDF11

0 20 40 60 80

100

1000

Days

Serum mAb

(ug/mL)

IBIO-600

Weeks post dose

Change in lean mass

(%, from baseline)

4 8 12

-20

-10

Change in fat mass

(%, from baseline)

Weeks post dose

4 8 12

Single Dose Study in Obese NHPs

t1/2 = 52.4 days

Extended Half-life

Lean Mass Increase

Fat Mass Reduction

1. Francis, T., et al. Insights into human muscle biology from human primary skeletal muscle cell culture. J Muscle Res Cell Motil (2025) doi:10.1007/s10974-025-09696-w.

NHP study details: N=3, single 5 mg/kg IV dose on day 0. NHPs obese and aged 16-21 years. Body composition assessment: ROI (gluteal and thigh region) DEXA

- Data on file

Lean Mass Fat Mass

IBIO-600 in Phase 1 Clinical Development

Phase 1 SAD enrollment

is complete

JUNE 2026

• Randomized, placebo-controlled study in adults

with overweight or obesity

• Single-ascending dose ongoing; multiple-ascending dose cohorts planned

Safety & tolerability Human PK

Strategic significance

Assesses whether iBio’s half-life extension seen in

NHPs translates clinically.

Single Ascending Dose (SAD); Pharmacokinetics (PK) 1

Test Translation into Humans

Evaluates Safety and Tolerability of subcutaneously

administered IBIO-600

Establishes Safety and Tolerability

Provides the first human data package from an

internally developed iBio antibody.

Creates First Internal Clinical Readout

IBIO-800

Myostatin and Activin A

Bispecific Antibody

Why IBIO-800: PH-HFpEF Affects a Large, Poor-Prognosis Population with No

FDA-Approved PH-Specific Therapy

1. Humbert, et al. Eur Heart J. (2022); 2. Todd and Lai. Front Med. (2022); 3. Yu, et al. medRxiv.

(2025); 4. Levine, et al. T Cardiovasc Med. (2019); 5. Maron, et al. Eur Respir J. (2024); 6. Kozaily,

et al. Curr Hypertens Rep. (2024); 7. Pandey, et al. JACC Rev. (2021);

PH-HFpEF: Pulmonary Hypertension (PH) in Heart Failure With Preserved Ejection Fraction

(HFpEF); PAH: Pulmonary Arterial Hypertension

Why have current approaches fallen short?

PAH-directed vasodilators target precapillary

disease but have not shown consistent

benefit in Group 2 PH.5

Current HFpEF therapies (SGLT2 inhibitors

and finerenone) reduce morbidity and

symptoms, but none is approved to treat the

pulmonary vascular disease of PH-HFpEF.6

Patients are limited simultaneously by

cardiopulmonary remodeling and by

peripheral muscle dysfunction that caps

exercise capacity.7

Group 2 PH requires more than

vasodilation

HFpEF therapies do not directly target PH Two compartments at once

Disease modification in PH-HFpEF may require acting in more than one compartment;

remodeling in the heart and lung, and functional capacity in the periphery.

Fraction of pulmonary hypertension that

arises from left heart disease (Group 2)1

PH-HFpEF is the most common form2

65-80%

Newly diagnosed HFpEF patients who

develop pulmonary hypertension within

4.5 years3

~1 in 3

FDA-approved therapies specifically

recommended for pulmonary

hypertension associated with HFpEF

under current guidelines1,4

INPUTS

Targeted disease-relevant ligands

INTERVENTION CONVERGENT SIGNALING THERAPEUTIC INTENT

Activin A

GDF8 / Myostatin

GDF11

IBIO-800

Selective upstream

neutralization

Convergent ActRII

signaling

ActRIIA / ActRIIB +

ALK4 / ALK5

↓ pSMAD2/3

Intended pharmacology

↓ Cardiac fibrosis

↓ Pulmonary vascular remodeling

↑ Whole-body functional capacity

Designed for chronic subcutaneous dosing

NOT TARGETED BY IBIO-800

BMP9 BMP10 Activin B

Designed to cover disease-relevant breadth

without pathway-wide ligand trapping

IBIO-800: Selective Multi-specific by Design, targeting three disease-relevant

ligands (Activin A, Myostatin, GDF11)

IBIO-800: Human cells connect target biology to pharmacologic response

*Alpha-Smooth Muscle Actin (α-SMA); marker for fibroblast activation

Data on file 20

HFpEF

TGF-β, Activins,

GDF8/GDF11

Activated Cardiac

Fibroblast

α-SMA ↑

pSmad2/3 ↑

pSmad2/3

Ligands Induce α-SMA Expression in Human Cardiac Fibroblast Cell Line

α-SMA α-SMA α-SMA α-SMA

Vehicle GDF8 GDF11 Activin A

0.1 1 10 100 1000

1000

2000

3000

4000

Conc. (nM)

MFI(a-SMA)

Media only

GDF8

GDF11

Activin A

a-SMA

Functional Blockade

Disease-relevant ligand biology is active in human

cells and pharmacologically tractable.

Dual myostatin × Activin A blockade produces the strongest

functional response

Myo x ActA

Myostatin

Antibody

Ligand-driven biology is visible in human cells; combined antibody blockade produces strongest response

Why it matters

GDF8, GDF11 and

Activin A increase α-SMA signal versus

media, supporting a

ligand-driven fibrosis

mechanism.

Activin A

Antibody

Control

The Next Wave of

iBio Innovation

Early Preclinical

Programs

Harnessing Amylin Biology with Precision Targeting: iBio’s Engineered Antibody

Agonist Approach

1.Aronne, L.,et al.Progressive Reduction in Body Weight aft Treatment w/ Amylin Analog Pramlintide in Obese Subjects:A Phase 2, Randomized, Placebo-Controlled, Dose-Escalation Study. J Clin Endo Metab 92(8)(2007)

2. Ghosh, R.,Ghosh, S.,& Das, A.Understanding mechanism amylin aggregation:From identifying crucial segments-tracing dominant sequential events- modeling potential aggregation suppressors. Biochim Biophys Acta – Prot Proteomics 1871(1)

(2023) ; Selective Amylin Recetor Agonist: SARA, Dual Amylin and Calcitonin Receptor Agonist: DACRA

Why We Target Amylin

Validated metabolic hormone that promotes

satiety, slows gastric emptying, and reduces

postprandial glucose excursions

Clinical studies with amylin analogs confirm

efficacy in weight loss, but peptide-based

approaches may be sub-optimal (dosing,

tolerability, manufacturability)1,2

Amylin receptor-selective antibody agonists could

provide a differentiated profile, with potential for

longer duration of action and reduced side effects

alone or in combination therapy

DACRA*

J Gingell, J. et al. An allosteric role for receptor activity-modifying proteins in defining GPCR pharmacology. Cell Discov 2, 16012 (2016).

*Dual Amylin and Calcitonin Receptor Agonists

Calcitonin

Receptor

Amylin

Receptor 1

Amylin

Receptor 2

Amylin

Receptor 3

SARA

Selective Amylin Receptor Agonists (SARAs) (Rather Than

DACRAs) Have Potential as a More Precisely Targeted Obesity

Intervention

Platform

Technology

Toward Any Epitope on Any Drug Target

AI epitope engineering and Ab optimization unlock challenging targets

• Multi-layer technology platform

addresses multiple challenges in Ab

discovery

• Patented Epitope Steering

technology

• Single-step Ab StableHu x

Mammalian Display

• Masked (ShieldTx®) Antibodies

• T-cell engager panel (EngageTx )

iBio’s Discovery Engine

iBio’s Proprietary AI

Technology Platform

We use our Tech Stack to generate new IP against hard-to-drug

targets – from idea to Development Candidate in 7 months

• Selectively targets functional

epitopes

• Epitopes with complex modes of

action

• Unlocks novel target classes

• Accelerates discovery of Ab against

validated targets

AI-guided precision hits

that are epitope class

agnostic

• Gen AI creates mammalian display

libraries with phage-like diversity

• Single-shot multidimensional lead

optimization

• Compatible with multi-specific

antibody formats

• Antibody format agnostic

Generative AI meets mammalian

display: Ab optimization in 3

weeks

Engineered Epitopes Are Tailor-Made Solutions for Your Target of Interest

Generative AI

Protein Complexes

Stabilize junctional and/or

discontinuous epitopes

Target of Interest

Epitopes of Interest

Design scaffold supporting

native epitope structure

Membrane Proteins

Solubilize transmembrane

domains

Use Cases

membrane

Tech Stack: Mammalian Display Enables Rapid Whole Molecule

Optimization

Input library of

diverse

sequences,

formats, masks,

and linkers

Multi-dimensional cell

sorting selects for

high expression,

selective target

binding, and negative

off-target binding

Corporate

Summary

A Leadership Team with Deep Industry Experience

Martin Brenner, DVM, Ph.D.

CEO & CSO

Felipe Duran

CFO

Marc Banjak

CLO

Molly Carr, MD

CMO

Executive

Summary

Corporate Highlights

Differentiated Pipeline Aiming to

Solve for the Challenges of today’s

GLP1’s

Focus on increased quality of weight

loss (IBIO-610, IBIO-800)

Developability (IBIO-610)

Muscle preservation (IBIO-600)

Patented AI-Driven Discovery Tech

Stack

Advance a highly developable pre-clinical pipeline

Designed to solve high-value, hard-to-drug targets

Financial Highlights

 $88.0M in cash, cash

equivalents and debt

securities as of June 30,

2026

 ~64.3M shares outstanding

as of August 30, 2026

 ~87.3M shares issuable

upon exercise of pre-funded

warrants outstanding at an

exercise price of $0.001 per

share as of August 30, 2026

 Cash runway extends into

Q4 FY 2028

GRAPHIC

Filename: ibio-20260914xex99d1g001.jpg · Sequence: 3

Binary file (143032 bytes)

Download ibio-20260914xex99d1g001.jpg

GRAPHIC

Filename: ibio-20260914xex99d1g002.jpg · Sequence: 4

Binary file (259732 bytes)

Download ibio-20260914xex99d1g002.jpg

GRAPHIC

Filename: ibio-20260914xex99d1g003.jpg · Sequence: 5

Binary file (120126 bytes)

Download ibio-20260914xex99d1g003.jpg

GRAPHIC

Filename: ibio-20260914xex99d1g004.jpg · Sequence: 6

Binary file (119938 bytes)

Download ibio-20260914xex99d1g004.jpg

GRAPHIC

Filename: ibio-20260914xex99d1g005.jpg · Sequence: 7

Binary file (131778 bytes)

Download ibio-20260914xex99d1g005.jpg

GRAPHIC

Filename: ibio-20260914xex99d1g006.jpg · Sequence: 8

Binary file (165652 bytes)

Download ibio-20260914xex99d1g006.jpg

GRAPHIC

Filename: ibio-20260914xex99d1g007.jpg · Sequence: 9

Binary file (137837 bytes)

Download ibio-20260914xex99d1g007.jpg

GRAPHIC

Filename: ibio-20260914xex99d1g008.jpg · Sequence: 10

Binary file (141447 bytes)

Download ibio-20260914xex99d1g008.jpg

GRAPHIC

Filename: ibio-20260914xex99d1g009.jpg · Sequence: 11

Binary file (200999 bytes)

Download ibio-20260914xex99d1g009.jpg

GRAPHIC

Filename: ibio-20260914xex99d1g010.jpg · Sequence: 12

Binary file (128767 bytes)

Download ibio-20260914xex99d1g010.jpg

GRAPHIC

Filename: ibio-20260914xex99d1g011.jpg · Sequence: 13

Binary file (141271 bytes)

Download ibio-20260914xex99d1g011.jpg

GRAPHIC

Filename: ibio-20260914xex99d1g012.jpg · Sequence: 14

Binary file (145706 bytes)

Download ibio-20260914xex99d1g012.jpg

GRAPHIC

Filename: ibio-20260914xex99d1g013.jpg · Sequence: 15

Binary file (145523 bytes)

Download ibio-20260914xex99d1g013.jpg

GRAPHIC

Filename: ibio-20260914xex99d1g014.jpg · Sequence: 16

Binary file (145509 bytes)

Download ibio-20260914xex99d1g014.jpg

GRAPHIC

Filename: ibio-20260914xex99d1g015.jpg · Sequence: 17

Binary file (180971 bytes)

Download ibio-20260914xex99d1g015.jpg

GRAPHIC

Filename: ibio-20260914xex99d1g016.jpg · Sequence: 18

Binary file (141589 bytes)

Download ibio-20260914xex99d1g016.jpg

GRAPHIC

Filename: ibio-20260914xex99d1g017.jpg · Sequence: 19

Binary file (148372 bytes)

Download ibio-20260914xex99d1g017.jpg

GRAPHIC

Filename: ibio-20260914xex99d1g018.jpg · Sequence: 20

Binary file (215372 bytes)

Download ibio-20260914xex99d1g018.jpg

GRAPHIC

Filename: ibio-20260914xex99d1g019.jpg · Sequence: 21

Binary file (130023 bytes)

Download ibio-20260914xex99d1g019.jpg

GRAPHIC

Filename: ibio-20260914xex99d1g020.jpg · Sequence: 22

Binary file (183925 bytes)

Download ibio-20260914xex99d1g020.jpg

GRAPHIC

Filename: ibio-20260914xex99d1g021.jpg · Sequence: 23

Binary file (150210 bytes)

Download ibio-20260914xex99d1g021.jpg

GRAPHIC

Filename: ibio-20260914xex99d1g022.jpg · Sequence: 24

Binary file (181010 bytes)

Download ibio-20260914xex99d1g022.jpg

GRAPHIC

Filename: ibio-20260914xex99d1g023.jpg · Sequence: 25

Binary file (144434 bytes)

Download ibio-20260914xex99d1g023.jpg

GRAPHIC

Filename: ibio-20260914xex99d1g024.jpg · Sequence: 26

Binary file (169898 bytes)

Download ibio-20260914xex99d1g024.jpg

GRAPHIC

Filename: ibio-20260914xex99d1g025.jpg · Sequence: 27

Binary file (133235 bytes)

Download ibio-20260914xex99d1g025.jpg

GRAPHIC

Filename: ibio-20260914xex99d1g026.jpg · Sequence: 28

Binary file (107571 bytes)

Download ibio-20260914xex99d1g026.jpg

GRAPHIC

Filename: ibio-20260914xex99d1g027.jpg · Sequence: 29

Binary file (142963 bytes)

Download ibio-20260914xex99d1g027.jpg

GRAPHIC

Filename: ibio-20260914xex99d1g028.jpg · Sequence: 30

Binary file (109703 bytes)

Download ibio-20260914xex99d1g028.jpg

GRAPHIC

Filename: ibio-20260914xex99d1g029.jpg · Sequence: 31

Binary file (159027 bytes)

Download ibio-20260914xex99d1g029.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 37

v3.26.3

Document and Entity Information

Sep. 14, 2026

Document and Entity Information [Abstract]

Document Type

8-K

Document Period End Date

Sep. 14, 2026

Entity Registrant Name

iBio, Inc.

Entity Incorporation, State or Country Code

Entity File Number

001-35023

Entity Tax Identification Number

26-2797813

Entity Address, Address Line One

11750 Sorrento Valley Road, Suite 200

Entity Address, City or Town

San Diego

Entity Address State Or Province

Entity Address, Postal Zip Code

92121

City Area Code

979

Local Phone Number

446-0027

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock

Trading Symbol

IBIO

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

Entity Central Index Key

0001420720

Amendment Flag

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration